Drug intelligence / Profile preview

folinic acid + fluorouracil + oxaliplatin + bevacizumab + everolimus

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy consisting of the FOLFOX chemotherapy regimen (folinic acid, fluorouracil, and oxaliplatin) plus bevacizumab (a VEGF inhibitor) and everolimus (an mTOR inhibitor). The combination leverages multiple mechanisms of action: cytotoxic effects from the chemotherapy agents, anti-angiogenic effects from bevacizumab, and cell growth inhibition from everolimus. This multi-targeted approach aims to enhance efficacy in treating advanced cancers.

Targets

mTOR (Mammalian target of rapamycin kinase)VEGFA (Vascular endothelial growth factor A)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on folinic acid + fluorouracil + oxaliplatin + bevacizumab + everolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on folinic acid + fluorouracil + oxaliplatin + bevacizumab + everolimus.

Explore the full profile